Newsletter
Shilpa Medicare has signed a binding agreement with Switzerland-based NXI Therapeutics AG to develop and manufacture a new drug candidate.
Breaking it down: the manufacturing agreement is for a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders.
Autoimmune and alloimmune disorders are conditions where the body’s immune system mistakenly attacks its own cells or reacts against foreign tissues.
Shilpa will handle end-to-end responsibilities.
Big theme: autoimmune and immune-modulation therapies are among the fastest-growing segments in global pharma.
The global autoimmune disease treatment market is estimated at roughly $130–150 billion today and is projected to cross $200 billion by 2030.
Within that, biologics and targeted immunotherapies are the fastest-growing segment, often priced at a premium.
Some blockbuster autoimmune drugs individually generate $10–20 billion annually (for example, therapies in rheumatoid arthritis, psoriasis, and inflammatory bowel disease).
